- Tytuł:
- Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
- Autorzy:
- Temat:
-
CHRONIC lymphocytic leukemia
COST effectiveness
CLINICAL trials
PROGRESSION-free survivalDRUG prices - Źródło:
- PharmacoEconomics; Apr2024, Vol. 42 Issue 4, p409-418, 10p
Czasopismo naukowe